Gateway 2011: Ropack Inc. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gateway 2011: Ropack Inc.



Your online Gateway to Ropack Inc. in 2011

10801 Mirabeau Street,
Montreal QC H1J 1T7
513 846-0921
www.ropack.com

About Ropack Inc.

 

Watch our video

 

Ropack offers turnkey primary and secondary pharmaceutical packaging services of solid oral dosages, tablets, powder, and encapsulation into blisters, pouches, bottles, stick packaging and carded blisters. Ropack recently added syringe assembly and vial labeling capabilities. Facilities are cGMP compliant, FDA certified and have 25 Class 100000 production rooms. Ropack is competitive, flexible and agile, supporting clinical trials, short-run start-ups, commercial production for more than 100 U.S., Canadian and European pharmaceutical customers.

 

Ropack has more than ten years of experience packaging temperature- and humidity-sensitive materials.  Our proven record of accomplishment in new product launches will support and accelerate your go-to-market timeline.

See what's new from Ropack's turnkey primary and secondary pharmaceutical and nutraceutical packaging services, including the latest advancements in blisters at Interphex 2011.Now Ropack offers stick packaging – slim, tube-shaped uni-dose packaging of solid oral dosage in a low relative humidity, controlled residual oxygen and temperature-controlled environment.  Stick packaging is popular in Japan and Europe for its accuracy and convenience, and now Ropack is advancing stick packaging technology in North America. 

Ropack now offers manufacturing and packaging environments to meet even the most exacting specifications.  A new 15,000-square-foot dedicated production suite is temperature-controlled with low RH (20%) and controlled residual oxygen (< 2%). Like all Ropack facilities, it is cGMP compliant, FDA certified and Health Canada approved.

 

New Products
and Releases
New Whitepapers

Ropack Enhances Services with Controlled Production Environment

Stick packaging

 

 

For more information:

To schedule a meeting, call or text Paul Dupont, Director of Business Development, at 513 846-0921, or email him: paul.dupont@ropack.com.

 

 



ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search

Click here